Accessibility Menu
Senti Biosciences logo

Senti Biosciences(NASDAQ) SNTI

Market Cap$11.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 YearN/A
1 Month-66%
$0.35
-1.81%
-0.01Today
Senti Biosciences last closing stock price
MetricPriceDate
Last closeUSD 0.352026-08-07
Senti Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.88%USD 0.342026-07-31
1 month-65.99%USD 1.042026-07-08
3 month-64.12%USD 0.992026-05-08
Since inception-99.65%USD 99.802021-05-26

Senti Biosciences Financials at a Glance

Market Cap

$11.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$38.00K

Net Income (TTM)

-$51.55M

EPS (TTM)

-$1.92

P/E Ratio

-0.18

Dividend

$0.00

Beta (Volatility)

2.14 (High)

Price

$0.35

Volume

81,278.671

Open

$0.37

Previous Close

$0.35

Daily Range

$0.35 - $0.37

52-Week Range

$0.33 - $1.15

Estimated Earnings Date

Aug 6, 2026

SNTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Senti Biosciences

Senti Biosciences develops cell therapies to help treat certain cancers. Its products aim to target cancer cells while sparing healthy ones. These therapies are designed for patients with hard-to-treat blood and solid tumors.

Lab Bench to Bedside: What Senti Sells

  • SENTI-202 (0% revenue): Cell therapy for acute myeloid leukemia, designed to attack cancer cells but avoid healthy bone marrow.
  • SENTI-301 (0% revenue): Cell therapy for liver cancer, aiming to target tumor cells in the liver.
  • SENTI-401 (0% revenue): Cell therapy for colorectal cancer, intended to spare healthy cells while attacking cancer.
  • Sublease Income (100% revenue): Income from leasing lab space to GeneFab, not related to product sales.

Plot Twists and Partnerships: Senti’s Growth Moves

  • Launched Phase 1 trial for SENTI-202 in 2024, with early data in April 2025.
  • Formed a collaboration with Celest Therapeutics in China for solid tumor research in 2024; trial enrollment stopped in April 2025.
  • Signed a manufacturing and sublease agreement with GeneFab in 2024 to support clinical production.
  • Closed a $47.6 million private placement in December 2024; all preferred shares converted to common stock by March 2025.
  • Established an at-the-market equity program in March 2025 for up to $17.5 million in new stock sales.

Why Senti Stands Out (Without the Lab Coat)

Senti uses a synthetic biology platform to program cell therapies for more precise cancer targeting. Its focus on “off-the-shelf” therapies could allow faster, broader patient access compared to custom-made treatments. The company relies on strategic partnerships for manufacturing and research support.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2023.
  • Operating expenses were $17 million in Q2 2025, up 25.8% year-over-year.
  • Net loss was $15 million in Q2 2025, up 31.5% from Q2 2024.
  • Cash and cash equivalents were $21.6 million as of June 30, 2025.

Bottom Line

Senti has shifted from research to early clinical trials, focusing on cancer therapies. The company remains pre-revenue and depends on external funding and partnerships to continue operations.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

39

CEO

Timothy K. Lu, MD, PhD

Headquarters

South San Francisco, CA 94080, US

SNTI Financials

Key Financial Metrics (TTM)

Gross Margin

-8513.16%

Operating Margin

-154810.53%

Net Income Margin

-135650.00%

Return on Equity

-503.79%

Return on Capital

-184.82%

Return on Assets

-134.80%

Earnings Yield

-5.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.14M

Volume

81.28K

Avg. Volume

249.63K

Financials (TTM)

Gross Profit

-$3.24M

Operating Income

-$58.83M

EBITDA

-$47.81M

Operating Cash Flow

-$36.88M

Capital Expenditure

-$196.00K

Free Cash Flow

-$37.07M

Cash & ST Invst.

$8.94M

Total Debt

$19.14M

Senti Biosciences Performance Analysis

Senti Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,286,00055.2%
20232023-12-31USD 2,561,000-40.2%
20242024-12-31USD 0N/A
20252025-12-31USD 22,000N/A
Senti Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-27.3%
Senti Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -22.29-88.3%
20232023-12-31USD -20.94-6.1%
20242024-12-31USD -12.04-42.5%
20252025-12-31USD -2.73-77.3%
Senti Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3081.8%
Q32025-09-30-23.2%
Q42025-12-3123.2%
Q12026-03-3173.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$16.00K

N/A

Gross Profit

$16.00K

+101.7%

Gross Margin

100.00%

N/A

Market Cap

$11.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$282.46K

N/A

Employees

39

N/A

Net Income

-$4.22M

+70.1%

EBITDA

-$3.53M

+72.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.94M

-73.6%

Total Debt

$19.14M

-41.0%

Accounts Receivable

$765.00K

-65.5%

Inventory

$0.00

N/A

Long Term Debt

$13.25M

-52.1%

Short Term Debt

$5.89M

+22.4%

Return on Assets

-1.35%

N/A

Return on Invested Capital

-2.45%

N/A

Free Cash Flow

-$7.48M

+46.8%

Operating Cash Flow

-$7.48M

+46.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDCXMedicus Pharma Ltd. Common Stock
$0.32+8.24%
BRNSBarinthus Biotherapeutics plc
$0.60+0.15%
GNTAGenenta Science S.p.A.
$1.30+0.00%
COEPCoeptis Therapeutics Holdings, Inc.
$10.99-8.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$134.54+0.01%
ACHRArcher Aviation
$6.21+0.11%
NVDANvidia
$219.15-0.02%
ONDSOndas
$9.28+0.02%

Questions About SNTI

What is the current price of Senti Biosciences?

Senti Biosciences is trading at $0.35 per share.

What is the 52-week range for Senti Biosciences?

Over the past 52 weeks, Senti Biosciences has traded between $0.33 and $1.15.

How much debt does Senti Biosciences have?

As of the most recent reporting period, Senti Biosciences reported total debt of $19.14M.

How much cash does Senti Biosciences have on hand?

Senti Biosciences reported $8.94M in cash and cash equivalents in its most recent financial results.

What is Senti Biosciences’s dividend yield?

Senti Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services